Sign in

BEATW on Nasdaq

HeartBeam, Inc.

In its 2026 annual report the company says: “HeartBeam is a medical technology company focused on transforming cardiac care through the power of personalized insights. Our aim is to deliver innovative, higher resolution ambulatory cardiac monitoring solutions that can be used by patients anywhere to enable the detection and monitoring of cardiac disease outside of a healthcare facility.”3 It is headquartered in Santa Clara, California.1 Its shares trade on Nasdaq under the symbol BEATW.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerBEATW on Nasdaq1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersSanta Clara, California1
  • Incorporated inDE2
  • Business address2118 Walsh Ave., Suite 210, Santa Clara, Ca 950502
  • Filer category, Emerging growth company2

See how the biggest companies compare on our leaderboards

HeartBeam is a medical technology company focused on transforming cardiac care through the power of personalized insights. Our aim is to deliver innovative, higher resolution ambulatory cardiac monitoring solutions that can be used by patients anywhere to enable the detection and monitoring of cardiac disease outside of a healthcare facility. Our ability to develop higher resolution Electrocardiogram (“ECG”) solutions is achieved through the development of our proprietary and patented technology platform that allows us to collect the heart’s electrical activity from three dimensions and synthesize a 12-Lead (“12L”) ECG from these signals.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45678-$21.1M in 2025+2583% since 2020
-$30.0M-$20.0M-$10.0M02020: -$788.0K-$788.0K20202021: -$2.3M-$2.3M2021+190%2022: -$13.0M-$13.0M2022+470%2023: -$15.3M-$15.3M2023+18%2024: -$19.9M-$19.9M2024+30%2025: -$21.1M-$21.1M2025+6%
Net income45678-$21.0M in 2025+1868% since 2020
-$30.0M-$20.0M-$10.0M02020: -$1.1M-$1.1M20202021: -$4.4M-$4.4M2021+315%2022: -$13.0M-$13.0M2022+193%2023: -$14.6M-$14.6M2023+13%2024: -$19.4M-$19.4M2024+33%2025: -$21.0M-$21.0M2025+8%

Every line of the income statement as filed: the last 2 fiscal years, latest first.8

Period ending2025-12-312024-12-31
General and administrative$7.7M$8.8M
Research and development$13.4M$11.1M
Total operating expenses$21.1M$19.9M
Loss from operations-$21.1M-$19.9M
Interest income$122.0K$446.0K
Other income and expense (net)$2.0K-$7.0K
Total other income$124.0K$439.0K
Loss before provision for income taxes-$21.0M-$19.4M
Income tax provision$0$0
Net Loss-$21.0M-$19.4M
Net loss per share, basic (in dollars per share)-$0.62-$0.73
Net loss per share, diluted (in dollars per share)-$0.62-$0.73
Weighted average common shares outstanding, basic (in shares)33.7M shares26.6M shares
Weighted average common shares outstanding, diluted (in shares)33.7M shares26.6M shares

Compare HeartBeam, Inc. with another company

Corporate structure

HeartBeam, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of HeartBeam, Inc.

  • Mark E. Strome Filed SCHEDULE 13D/A on HeartBeam, Inc., latest Aug 13, 2026 (2 filings since Oct 25, 2023)
  • PUBLIC VENTURES, LLC Filed SC 13D on HeartBeam, Inc., latest Aug 28, 2023
  • Andrew Schwartzberg Filed SC 13D on HeartBeam, Inc., latest Jun 2, 2023
  • Ionic Ventures, LLC Filed SC 13G/A on HeartBeam, Inc., latest Feb 13, 2023 (3 filings since Nov 16, 2021)
  • SABBY MANAGEMENT, LLC Filed SC 13G/A on HeartBeam, Inc., latest Jan 10, 2023 (3 filings since Nov 17, 2021)
  • HeartBeam, Inc. Santa Clara, California

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What HeartBeam, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$1.1M8 Dec 31, 2025$450.0K8 Dec 31, 2024+144.9%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$4.4M8 Dec 31, 2025$2.4M8 Dec 31, 2024+84.3%

Inventory

ItemLatestA year beforeChange
Inventory, total$103.0K8 Dec 31, 2025$08 Dec 31, 2024

Properties, in its own words

Our headquarters are located at 2118 Walsh Avenue, Suite 210, Santa Clara, CA 95050 which we lease pursuant to a monthly lease agreement entered into in May 2019 by our founder Branislav Vajdic. The terms of the lease are month to month and either party can terminate with one months’ notice. We terminated this lease effective on January 11, 2024, and entered into a new lease in name of the Company with the same landlord. The new lease commenced on February 1, 2024, for initial period of 3 years. In December 2025, the Company signed its first amendment to this lease with landlord and extending the lease for additional period of 2 years to expire in January 2028.

We believe that the facilities described above are suitable and adequate for our present purposes and needs in the near future.

Item 2 of the 10-K filed Mar 12, 2026.3

Leadership

Who has led HeartBeam, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Branislav Vajdic2021–2025
  2. Robert Paul Eno2025–now

President

  1. Robert Paul Eno2023–2025
  2. Branislav Vajdic2025–now

Chief financial officer

  1. Richard D. Brounstein2021–2023
  2. Tim Cruickshank2024–now

Chief operating officer

  1. Alan Baumel2021–2022
2025
Board members and other officers (10)

Timeline

  1. Aug 14, 20268-K Entered a material agreement26
  2. Aug 6, 20268-K Executive or director change27
  3. Aug 3, 20268-K Shareholder vote28
  4. Jul 2, 20268-K Listing notice or transfer29
  5. Jun 24, 20268-K Executive or director change; Other events30
  6. Jun 22, 20268-K Executive or director change31
  7. Apr 16, 20268-K Entered a material agreement; Other events32
  8. Nov 21, 20258-K Other events33
  9. Jul 16, 20258-K Shareholder vote34
  10. May 5, 20258-K Executive or director change; Regulation FD disclosure35
  11. May 1, 2025New chief executive Robert Paul Eno becomes CEO11
  12. Apr 25, 20258-K Change of auditor36
  13. Feb 26, 20258-K Other events37
  14. Nov 12, 2021New chief executive Branislav Vajdic becomes CEO12

Filings

262 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 41 major events, 131 insider forms, 10 large holders, 60 other. The latest 20:

  1. Oct 9, 20264 EDGAR
  2. Oct 9, 20264 EDGAR
  3. Oct 9, 20264 EDGAR
  4. Oct 9, 20264 EDGAR
  5. Oct 9, 20264 EDGAR
  6. Oct 9, 20264 EDGAR
  7. Aug 14, 20268-K CURRENT REPORT EDGAR
  8. Aug 14, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR
  9. Aug 13, 2026SCHEDULE 13D/A EDGAR
  10. Aug 13, 202610-Q EDGAR
  11. Aug 6, 20268-K/A AMENDMENT NO. 1 TO FORM 8-K EDGAR
  12. Aug 3, 20268-K CURRENT REPORT EDGAR
  13. Jul 24, 20264 OWNERSHIP DOCUMENT EDGAR
  14. Jul 24, 20264 OWNERSHIP DOCUMENT EDGAR
  15. Jul 24, 20264 OWNERSHIP DOCUMENT EDGAR
  16. Jul 2, 20268-K CURRENT REPORT EDGAR
  17. Jun 25, 2026DEFA14A DEFINITIVE ADDITIONAL MATERIALS EDGAR
  18. Jun 24, 20268-K CURRENT REPORT EDGAR
  19. Jun 22, 20268-K CURRENT REPORT EDGAR
  20. Jun 18, 2026DEF 14A EDGAR

The 262 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

33 open-market trades by officers, directors and large owners since October 2021: 14 buys and 19 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 16, 2026Ferrari RichardDirectorBuy57,500$0.80$46.0KForm 4
Apr 16, 2026Cruickshank TimCFOBuy31,250$0.80$25.0KForm 4
Apr 16, 2026Elfrink WillemDirectorBuy187,500$0.80$150.0KForm 4
Apr 16, 2026JAFF MICHAEL RDirectorBuy31,250$0.80$25.0KForm 4
Apr 16, 2026Vajdic BranislavPresidentBuy31,250$0.80$25.0KForm 4
Apr 16, 2026Ferrari RichardDirectorBuy62,500$0.80$50.0KForm 4
Apr 16, 2026ENO Robert PaulPresidentBuy12,500$0.80$10.0KForm 4
Apr 16, 2026Ortigas-Wedekind MargaDirectorBuy25,000$0.80$20.0KForm 4
Apr 16, 2026STROME MARK EDirectorBuy750,000$0.80$600.0KForm 4
Dec 18, 2025de Urioste GeorgeDirectorSale33,185$2.83$93.9KForm 4
Dec 17, 2025STROME MARK EDirectorSale250,000$3.58$895.0KForm 4
Dec 17, 2025de Urioste GeorgeDirectorSale23,961$3.68$88.2KForm 4
Feb 14, 2025Ferrari RichardDirectorBuy29,412$1.70$50.0KForm 4
Feb 14, 2025Cruickshank TimCFOBuy17,647$1.70$30.0KForm 4
Sep 6, 2024de Urioste GeorgeDirectorSale1,674$2.34$3.9KForm 4
Aug 30, 2024de Urioste GeorgeDirectorSale5,500$2.31$12.7KForm 4
Aug 27, 2024de Urioste GeorgeDirectorSale2,194$2.26$5.0KForm 4
Aug 26, 2024de Urioste GeorgeDirectorSale300$2.38$714Form 4
Aug 23, 2024de Urioste GeorgeDirectorSale2,500$2.30$5.8KForm 4
Sep 29, 2023de Urioste GeorgeDirectorSale5,500$2.06$11.3KForm 4

All 33 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Robert Eno58$360.0K$1.0M43
2025Branislav VajdicPhD72$404.1K$946.0K43
2025Timothy Cruickshank$346.5K$729.5K43
2025Kenneth Persen$312.0K$426.8K43
2024Chief Financial Officer$120.3K$976.4K43
2024President(Former Chief Executive Officer)$449.0K$626.8K43
2024Chief Executive Officer(Former President)$379.4K$490.7K43
2024Chief System DeploymentOfficer$310.0K$371.8K43

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Armistice Capital, LLC500,000$14.0K0.0%No change
Clear Street Group Inc.16,611$4650.0%No change
D'Orazio & Associates, Inc.16,000$4530.0%No change
Two Sigma Securities, LLC11,653$3300.0%−246
Wells Fargo & Company/mn7,500$2100.0%No change
UBS Group AG3,837$1070.0%+1,880

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How HeartBeam, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARHeartBeam, Inc.1
  • CIK0001779372
  • Employer ID (EIN)47-48814503
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address2118 Walsh Ave., Suite 210, Santa Clara, CA 950501
  • Phone408-899-44431
  • Shares outstanding56,349,171 as of Aug 11, 202610
  • Public float$36.4M as of Jun 30, 20253
  • AuditorCBIZ CPAs P.C., Saddle Brook, New Jersey PCAOB ID 199; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceAug 16, 20191
  • Filings271 in all: 4 (112), 8-K (40), 10-Q (15), 3 (14), CORRESP (8), S-1/A (8), 424B5 (6), DEF 14A (6)1
    All 34 form types

    PRE 14A (6), UPLOAD (6), 10-K (5), 4/A (4), EFFECT (4), SC 13G/A (4), 424B2 (3), S-8 (3), SC 13D (3), 424B1 (2), DRS (2), DRS/A (2), FWP (2), S-1 (2), S-3 (2), SC 13G (2), 3/A (1), 8-A12B (1), 8-K/A (1), CERT (1), D (1), DEFA14A (1), DEL AM (1), DRSLTR (1), S-3/A (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 12, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Jun 18, 2026
    Latest 8-K (8-K) Aug 14, 2026

Securities registered for trading

ClassSymbolExchange
Common StockBEATNASDAQ
WarrantsBEATWNASDAQ

From the cover page of the 10-K filed Mar 12, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks HeartBeam, Inc. names in Item 1A of its 10-K filed Mar 12, 2026: 50 risks under these headings, as written.3

  • You should consider carefully the risks, uncertainties and other factors described below, in addition to the other information set forth in this Form 10-K, before making an investment decision. Any of these risks, uncertainties and other factors could materially and adversely affect our business, financial condition, results of operations, cash flows or prospects. In that case, the market price of our common stock could decline, and you may lose all or part of your investment in our common stock. See also “Cautionary Statement Regarding Forward-Looking Statements.”
  • Risks Related to Our Business
  • We require additional capital to support our present business plan and our anticipated business growth, and such capital may not be available on acceptable terms, or at all, which would adversely affect our ability to operate.
  • We cannot predict our future capital needs and we may not be able to secure additional financing.
  • We have a limited operating history upon which investors can evaluate our future prospects.
  • Management and our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.
  • We have no revenues and we cannot predict when we will achieve first revenues and sustained profitability.
  • We may never complete the development and commercialization of products that we are currently developing and future development of new generations of any of our other proposed products.
  • We may not meet our product development and commercialization milestones.
  • Our business is dependent upon physicians utilizing and prescribing our solution; if we fail to engage physicians to utilize our solution, our revenues may never materialize or may not meet our projections.
  • We are subject to extensive governmental regulations relating to the manufacturing, labeling, and marketing of our products.
  • If we are not able to both obtain and maintain adequate levels of third-party reimbursement for our products, it would have a material adverse effect on our business.
The other 39 risks
  • Changes in reimbursement practices of third-party payers could affect the demand for our products and services and our revenue levels.
  • We may experience difficulty in obtaining reimbursement for our services from commercial payers that consider our technology to be experimental and investigational, which would adversely affect our revenue and operating results.
  • Reimbursement by Medicare is highly regulated and subject to change; our failure to comply with applicable regulations could decrease our expected revenue and may subject us to penalties or have an adverse impact on our business.
  • Consolidation of commercial payers could result in payers eliminating coverage of mobile cardiac monitoring solutions or reducing reimbursement rates.
  • Product defects could adversely affect the results of our operations.
  • Interruptions or delays in telecommunications systems or in the data services provided to us by cellular communication providers or the loss of our wireless or data services could impair the delivery of our cardiac monitoring services.
  • Interruptions in computing and data management cloud systems could impair the delivery of our cardiac monitoring services.
  • We could be exposed to significant liability claims if we are unable to obtain insurance at acceptable costs and adequate levels or otherwise protect ourselves against potential product liability claims.
  • The results of our research and development efforts are uncertain and there can be no assurance of the commercial success of our products.
  • If we fail to retain certain of our key personnel and attract and retain additional qualified personnel, we might not be able to pursue our growth strategy.
  • We will not be profitable unless we can demonstrate that our products can be manufactured at low prices.
  • Our dependence on a limited number of suppliers may prevent us from delivering our devices on a timely basis.
  • We rely significantly on information technology and any failure, inadequacy, or security lapse of that technology, including any cybersecurity incidents, could harm us.
  • We cannot provide assurances that in the future there will be no weaknesses in our internal controls and that they will be effectively remediated if any were to occur in the future.
  • Risks Related to Economic Conditions
  • We maintain our cash at financial institutions, often in balances that exceed federally insured limits.
  • Changes in tax laws or regulations may increase tax uncertainty and adversely affect results of our operations and our effective tax rate.
  • Escalating global trade tensions, the Russia and Ukraine war, the Israel-Hamas war, the adoption or expansion of tariffs and trade restrictions and economic disruption and uncertainty resulting therefrom could negatively impact us.
  • Natural disasters and other events beyond our control could materially adversely affect us.
  • Our business and operations, and the operations of our suppliers and customers, have been, and may in the future be adversely affected by epidemics, pandemics or other public health crises such as the COVID-19 pandemic outbreak.
  • Risks Related to Our Industry
  • The industry in which we operate is highly competitive and subject to rapid technological change. If our competitors are better able to develop and market products that are safer, more effective, less costly, easier to use, or are otherwise more attractive, we may be unable to compete effectively with other companies.
  • We face competition from other medical device companies that focus on similar markets.
  • Unsuccessful clinical trials or procedures relating to products under development could have a material adverse effect on our prospects.
  • Intellectual property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • If we are unable to protect our proprietary rights, or if we infringe on the proprietary rights of others, our competitiveness and business prospects may be materially damaged.
  • Dependence on our proprietary rights and failing to protect such rights or to be successful in litigation related to such rights may result in our payment of significant monetary damages or impact offerings in our product portfolios.
  • Enforcement of federal and state laws regarding privacy and security of patient information may adversely affect our business, financial condition or operations.
  • We may become subject, directly or indirectly, to federal and state health care fraud and abuse laws and regulations and if we are unable to fully comply with such laws, the Company could face substantial penalties.
  • We may be subject to federal and state false claims laws which impose substantial penalties.
  • Risks Related To Common Stock
  • The price of our Common Stock and Warrants may be subject to wide fluctuations.
  • We are an “emerging growth company,” and any decision on our part to comply with certain reduced disclosure requirements
  • We are a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors.
  • Future sales and issuances of our Common Stock or rights to purchase Common Stock, including pursuant to our equity incentive plans and other equity securities could result in dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
  • Nasdaq Capital Market, may delist our Common Stock if we fail to comply with ongoing listing standards.
  • If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.
  • Our need for future financing may result in the issuance of additional securities which will cause investors to experience dilution.
  • If our shares become subject to the penny stock rules, it would become more difficult to trade our shares.
  • Liability of directors for breach of duty is limited under Delaware law.
  • We do not anticipate paying any cash dividends on our Common Stock in the foreseeable future and, as such, capital appreciation, if any, of our Common Stock will be your sole source of gain for the foreseeable future.

Legal proceedings

There are no actions, suits, proceedings, inquiries or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our Common Stock, any of our officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
    SEC EDGAROther events
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43